Briacell Therapeutics Corp (BCTX) - Net Assets
Based on the latest financial reports, Briacell Therapeutics Corp (BCTX) has net assets worth $9.35 Million USD as of October 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($13.08 Million) and total liabilities ($3.72 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check how resilient are Briacell Therapeutics Corp's assets to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $9.35 Million |
| % of Total Assets | 71.51% |
| Annual Growth Rate | 34.98% |
| 5-Year Change | -31.09% |
| 10-Year Change | 2927.91% |
| Growth Volatility | 231.78 |
Briacell Therapeutics Corp - Net Assets Trend (2006–2025)
This chart illustrates how Briacell Therapeutics Corp's net assets have evolved over time, based on quarterly financial data. Also explore BCTX current and non-current assets for the complete picture of this company's asset base.
Annual Net Assets for Briacell Therapeutics Corp (2006–2025)
The table below shows the annual net assets of Briacell Therapeutics Corp from 2006 to 2025. For live valuation and market cap data, see market cap of Briacell Therapeutics Corp.
| Year | Net Assets | Change |
|---|---|---|
| 2025-07-31 | $23.83 Million | +739.42% |
| 2024-07-31 | $-3.73 Million | +26.11% |
| 2023-07-31 | $-5.04 Million | -138.08% |
| 2022-07-31 | $13.25 Million | -61.70% |
| 2021-07-31 | $34.58 Million | +1061.33% |
| 2020-07-31 | $-3.60 Million | -422.38% |
| 2019-07-31 | $-688.66K | -172.87% |
| 2018-07-31 | $945.02K | +25.96% |
| 2017-07-31 | $750.23K | -4.68% |
| 2016-07-31 | $787.11K | -32.09% |
| 2015-07-31 | $1.16 Million | +102945.96% |
| 2014-07-31 | $-1.13K | -100.01% |
| 2013-07-31 | $9.33 Million | -6.99% |
| 2012-07-31 | $10.03 Million | -13.70% |
| 2011-07-31 | $11.63 Million | +705.84% |
| 2010-07-31 | $1.44 Million | +48.08% |
| 2009-07-31 | $974.50K | +166.86% |
| 2008-07-31 | $365.17K | -18.25% |
| 2007-07-31 | $446.71K | +459.67% |
| 2006-07-31 | $79.82K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Briacell Therapeutics Corp's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 15364562900.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (July 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $139.88 Million | 568.99% |
| Other Comprehensive Income | $38.36 Million | 156.01% |
| Total Equity | $24.58 Million | 100.00% |
Briacell Therapeutics Corp Competitors by Market Cap
The table below lists competitors of Briacell Therapeutics Corp ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
GREMI MEDIA S.A. ZY 4
F:4C8
|
$27.63 Million |
|
Zhejiang Yuancheng Landscape
SHG:603388
|
$27.65 Million |
|
Izostal SA
WAR:IZS
|
$27.67 Million |
|
Etiler İnci Bufe Gida Sanayi ve Dis Ticaret AS
IS:ETILR
|
$27.68 Million |
|
YoungWoo DSP Co.Ltd
KQ:143540
|
$27.62 Million |
|
Lisata Therapeutics Inc.
NASDAQ:LSTA
|
$27.61 Million |
|
Hunyvers SA
PA:ALHUN
|
$27.60 Million |
|
Celularity Inc
NASDAQ:CELU
|
$27.60 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Briacell Therapeutics Corp's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -3,307,309 to 24,584,605, a change of 27,891,914.
- Net loss of 36,495,163 reduced equity.
- Other comprehensive income increased equity by 38,547,767.
- Other factors increased equity by 25,839,310.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-36.50 Million | -148.45% |
| Other Comprehensive Income | $38.55 Million | +156.8% |
| Other Changes | $25.84 Million | +105.1% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Briacell Therapeutics Corp's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.32x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2006-07-31 | $13.89 | $4.18 | x |
| 2007-07-31 | $107.15 | $4.18 | x |
| 2008-07-31 | $1132.21 | $4.18 | x |
| 2009-07-31 | $1636.57 | $4.18 | x |
| 2010-07-31 | $1191.59 | $4.18 | x |
| 2011-07-31 | $5339.04 | $4.18 | x |
| 2012-07-31 | $2558.61 | $4.18 | x |
| 2013-07-31 | $2373.22 | $4.18 | x |
| 2014-07-31 | $-0.29 | $4.18 | x |
| 2015-07-31 | $70.24 | $4.18 | x |
| 2016-07-31 | $40.93 | $4.18 | x |
| 2017-07-31 | $33.13 | $4.18 | x |
| 2018-07-31 | $33.14 | $4.18 | x |
| 2019-07-31 | $-17.82 | $4.18 | x |
| 2020-07-31 | $-75.59 | $4.18 | x |
| 2021-07-31 | $114.78 | $4.18 | x |
| 2022-07-31 | $12.82 | $4.18 | x |
| 2023-07-31 | $-4.84 | $4.18 | x |
| 2024-07-31 | $-3.01 | $4.18 | x |
| 2025-07-31 | $13.05 | $4.18 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Briacell Therapeutics Corp utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -148.45%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.21x
- Recent ROE (-148.45%) is below the historical average (-110.96%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2006 | -10.75% | 0.00% | 0.00x | 1.21x | $-16.56K |
| 2007 | -26.06% | 0.00% | 0.00x | 1.02x | $-161.08K |
| 2008 | -27.09% | 0.00% | 0.00x | 1.04x | $-135.44K |
| 2009 | -25.23% | 0.00% | 0.00x | 1.07x | $-343.28K |
| 2010 | -64.29% | 0.00% | 0.00x | 1.02x | $-1.07 Million |
| 2011 | -8.82% | 0.00% | 0.00x | 1.06x | $-2.19 Million |
| 2012 | -9.96% | 0.00% | 0.00x | 1.03x | $-2.00 Million |
| 2013 | -4.09% | 0.00% | 0.00x | 1.01x | $-1.32 Million |
| 2014 | 0.00% | 0.00% | 0.00x | 0.00x | $-8.89 Million |
| 2015 | -301.19% | 0.00% | 0.00x | 1.10x | $-3.61 Million |
| 2016 | -283.53% | 0.00% | 0.00x | 1.06x | $-2.31 Million |
| 2017 | -428.86% | 0.00% | 0.00x | 2.18x | $-3.29 Million |
| 2018 | -572.23% | 0.00% | 0.00x | 2.42x | $-5.50 Million |
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $-5.75 Million |
| 2020 | 0.00% | 0.00% | 0.00x | 0.00x | $-4.58 Million |
| 2021 | -50.97% | 0.00% | 0.00x | 2.10x | $-21.08 Million |
| 2022 | -257.63% | 0.00% | 0.00x | 4.12x | $-35.45 Million |
| 2023 | 0.00% | 0.00% | 0.00x | 0.00x | $-26.76 Million |
| 2024 | 0.00% | 0.00% | 0.00x | 0.00x | $-6.22 Million |
| 2025 | -148.45% | 0.00% | 0.00x | 1.21x | $-38.95 Million |
Industry Comparison
This section compares Briacell Therapeutics Corp's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $44,828,400
- Average return on equity (ROE) among peers: -124.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Briacell Therapeutics Corp (BCTX) | $9.35 Million | -10.75% | 0.40x | $27.62 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $3.60 Million | -91.89% | 0.28x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $448.19K |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $88.00 Million | -44.09% | 0.34x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $80.00K | -31.70% | 0.38x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $23.36 Million | -97.44% | 0.37x | $3.74 Billion |
About Briacell Therapeutics Corp
BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that… Read more